COMMUNIQUÉS West-GlobeNewswire

NICOX : Number of voting rights as of September 30, 2017

03/10/2017 - 17:45

Nicox SA Société anonyme with a registered capital of € 29,169,338 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On October 3, 2017, MONTHLY PUBLICATION OF THE [...]

Targovax granted US Patent for mutant-RAS neoantigen platform 2nd generation product TG02

03/10/2017 - 14:48

Extends IP protection of TG02 in the US until 09.12.2034 Oslo, 3 October 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target [...]

Advanced Bifurcation Systems Announces Plan for Human Clinical Trials in New Brunswick, Canada

03/10/2017 - 13:55

LOS ANGELES, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Advanced Bifurcation Systems ("ABS" or the "Company"), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of [...]

RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

03/10/2017 - 13:39

BEKINDA ® i 12 mg Phase II study successfully met its primary endpoint, improving primary efficacy outcome of stool consistency by an absolute difference of 19.4% vs. placebo and comparing favorably with previously [...]

Shire plc : Director/PDMR Shareholding

03/10/2017 - 13:00

Director/PDMR Shareholding October 3, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of transactions by persons discharging managerial responsibilities 1. Details of the person discharging managerial [...]

Saniona AB: Saniona obtains research milestone from The Michael J. Fox Foundation for Parkinson's Research

03/10/2017 - 12:45

PRESS RELEASE October 3, 2017 Saniona, a leading biotech company in the field of ion channels, today announces that it has reached the third research milestone for identifying new drug candidates for the treatment of [...]

Summit Therapeutics plc : Exercise of Options

03/10/2017 - 12:15

Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 3 October 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing [...]

AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundation for Parkinson's Research

03/10/2017 - 10:53

Continued development of PET tracer for earlier and more accurate diagnosis of Parkinson's disease Focuses on alpha-synuclein, a key protein in Parkinson's disease pathology Lausanne, Switzerland, - October 3, 2017 - AC [...]

Amer Sports third quarter 2017 results published on October 26

03/10/2017 - 09:30

Amer Sports Corporation PRESS RELEASE October 3, 2017 at 10:30 a.m. Amer Sports third quarter 2017 results published on October 26 Amer Sports Corporation will publish its third quarter 2017 results on Thursday, October [...]

PharmaMar will participate at the 17th European Large & MidCap Event to be held in Paris

03/10/2017 - 09:00

On October 4 th and 5th, PharmaMar will meet with European investors to increase awareness of the Company and to explain in detail present and future projects. This 17th annual event will host 400 international [...]

Solon Eiendom ASA :Primary insider notification

03/10/2017 - 08:30

(Oslo, Norway, 2 October 2017) Solon Eiendom ASA Board Member Tore Aksel Voldberg (through his wholly owned company Skøien AS) has today bought 10 587 shares in Solon Eiendom ASA at a price of NOK 18,5000. Following [...]

Santhera Presents Data and Hosts Symposium on Respiratory Function Decline in Duchenne Muscular Dystrophy at the World Muscle Society Congress

03/10/2017 - 07:00

Liestal, Switzerland, October 3, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces that it will present additional data from the positive Phase III DELOS trial in patients with Duchenne muscular dystrophy (DMD) at [...]

ABLYNX FILES REGISTRATION STATEMENT FOR A PROPOSED GLOBAL OFFERING

02/10/2017 - 23:06

REGULATED INFORMATION - INSIDE INFORMATION GHENT, Belgium, 2 October 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] , a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform to [...]

Nightstar Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

02/10/2017 - 22:05

LEXINGTON, Mass. and LONDON, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc ("Nightstar" or the "Company") (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited [...]

NuCana plc Announces Closing of Initial Public Offering of ADSs and Exercise of Underwriters' Option to Purchase Additional ADSs

02/10/2017 - 20:27

EDINBURGH, United Kingdom, Oct. 02, 2017 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying its [...]

Ossur Hf : Transactions in relation to share buyback program

02/10/2017 - 18:00

Announcement from Össur hf. No. 70/2017 Reykjavík, 2 October 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]

GLOBAL BIOENERGIES : PUBLICATION DES RESULTATS SEMESTRIELS AU 30/06/2017

02/10/2017 - 17:37

GLOBAL BIOENERGIES : PUBLICATION DES RESULTATS SEMESTRIELS AU 30/06/2017 Perte nette du Groupe de 7,8 M€ sur le premier semestre 2017 Trésorerie nette de 8,4 M€ au 30 juin 2017, juste avant l'opération d'augmentation de [...]

GLOBAL BIOENERGIES: PUBLICATION OF THE HALF-YEAR RESULTS TO 30/06/2017

02/10/2017 - 17:37

GLOBAL BIOENERGIES: PUBLICATION OF THE HALF-YEAR RESULTS TO 30/06/2017 Net loss for the Group of €7.8 million in the first half of 2017 €8.4 million net cash at 30 June 2017, immediately prior to the €10.2 million [...]

Status regarding Novo Nordisk's holding of its own shares (30 September 2017)

02/10/2017 - 15:09

Bagsværd, Denmark, 2 October 2017 - In continuation of the company's announcements dated 3 May 2017 and 9 August 2017 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock [...]